Vasopressin injection - Par Pharmaceutical Companies

Drug Profile

Vasopressin injection - Par Pharmaceutical Companies

Alternative Names: Vasostrict

Latest Information Update: 29 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Par Pharmaceutical Companies
  • Class Antidiuretics; Antihaemorrhagics; Basic amino acids; Diamino amino acids; Hormones; Vasoconstrictors; Vasopressins
  • Mechanism of Action Vasopressin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypotension

Most Recent Events

  • 28 Jun 2016 Par Pharmaceuticals has patent protection for vasopressin injection in USA
  • 14 Nov 2014 Launched for Hypotension in USA (IV)
  • 12 Nov 2014 Registered for Hypotension in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top